Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy?
J Eur Acad Dermatol Venereol
.
2021 Jun;35(6):e355-e357.
doi: 10.1111/jdv.17175.
Epub 2021 Mar 5.
Authors
S Piaserico
1
,
P Gisondi
2
,
S Cazzaniga
3
4
,
G Girolomoni
2
,
P G Calzavara-Pinton
5
,
L Naldi
3
6
Affiliations
1
Department of Medicine, Section of Dermatology, University of Padua, Padua, Italy.
2
Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
3
Centro Studi GISED, Bergamo, Italy.
4
Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland.
5
Division of Dermatology, University of Brescia, Brescia, Italy.
6
Division of Dermatology, San Bortolo Hospital, Vicenza, Italy.
PMID:
33587774
PMCID:
PMC8014240
DOI:
10.1111/jdv.17175
No abstract available
Publication types
Letter
MeSH terms
Biological Therapy
COVID-19*
Humans
Psoriasis* / diagnosis
Psoriasis* / drug therapy
SARS-CoV-2